
- /
- Supported exchanges
- / US
- / BIOA.NASDAQ
BioAge Labs, Inc (BIOA NASDAQ) stock market data APIs
BioAge Labs, Inc Financial Data Overview
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with BioAge Labs, Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get BioAge Labs, Inc data using free add-ons & libraries
Get BioAge Labs, Inc Fundamental Data
BioAge Labs, Inc Fundamental data includes:
- Net Revenue: 3 863 K
- EBITDA: -91 149 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: -0.3814
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioAge Labs, Inc News

FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's
BioArctic has seen a significant price movement of 41% over the past quarter. This surge is closely tied to several positive developments, including an impressive earnings report where the company pos...


BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025
STOCKHOLM, Sept. 9, 2025 /PRNewswire/ -- Uppsala University announced today that BioArctic AB's(publ) (NASDAQ STOCKHOLM: BIOA B) CEO, Gunilla Osswald, has been awarded the title Alumnus of the Year 20...

BioArctic's founders intend to divest minor part of their shareholding
STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA-B) has been made aware that the company's two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, in...

Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated a rolling submission of the Supplemental Biologics Lice...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.